The rise of COVID-19 cases around the world has paved a way to create a need for prevention that can at least decrease/ prevent the worst symptoms of SARS-CoV-2. There is growing evidence of clinical trials for immunity booster and that vaccines like BCG could help with the same. A new report published in the American Society for Microbiology’s journal “mBio” suggested the same about the MMR vaccine. Adults who received the MMR vaccine as a child will likely still have antibodies against the MMR virus. Studies show that these vaccines protect against other infections by ‘training’ the immune system in a non-specific way. This type of non-specific immune response is the first line of defence against infection and is called the innate immune response. The researchers have proposed a clinical trial of the MMR vaccine in high-risk healthcare workers and first responders in New Orleans. They have also been awarded a grant to compare the MMR and BCG vaccines in a primate model of COVID-19. If their hypothesis is correct, the authors say use of the MMR vaccine could present a ‘low-risk-high-reward’ measure to save lives during the COVID-19 pandemic.